Code usapeptidevendors: 25% off everything at · Purgo Labs

Related brand · disclosed
USA Peptide VendorsIndependent vendor reviews
Purgo Labsusapeptidevendors

Try

Original illustration for Tesamorelin research notes: abstract molecular artwork in orange and teal
Original illustration by USA Peptide Vendors; artistic, not a structural model.

Growth & signaling research peptides

Tesamorelin: from sequence to supplier

Full-length GHRH(1-44) analogue stabilised with a trans-3-hexenoyl group on the N-terminal tyrosine. Tesamorelin's best-known trial reduced visceral fat in people with HIV-associated lipodystrophy.

GrowthCAS 218949-48-544 residuesTesamorlin (Purgo spelling)Updated 2026-11-09

  1. Confirm what Tesamorelin is

    Amino acid sequence · 44 residues
    1. Y1
    2. A2
    3. D3
    4. A4
    5. I5
    6. F6
    7. T7
    8. N8
    9. S9
    10. Y10
    11. R11
    12. K12
    13. V13
    14. L14
    15. G15
    16. Q16
    17. L17
    18. S18
    19. A19
    20. R20
    21. K21
    22. L22
    23. L23
    24. Q24
    25. D25
    26. I26
    27. M27
    28. S28
    29. R29
    30. Q30
    31. Q31
    32. G32
    33. E33
    34. S34
    35. N35
    36. Q36
    37. E37
    38. R38
    39. G39
    40. A40
    41. R41
    42. A42
    43. R43
    44. L44

    GHRH(1-44) with an N-terminal trans-3-hexenoyl group (Hex). This chain reproduces KEGG's molecular formula exactly; KEGG's printed residue list drops valine 13.

    CAS number
    218949-48-5
    Molecular formula
    C221H366N72O67S
    Molecular weight
    5135.78 g/mol
    PubChem CID
    16137828
    Length
    44 residues

    Verified 2026-11-09 against KEGG DRUG D06655 and PubChem CID 16137828. Values we couldn't verify are left out.

  2. Know the proposed mechanism

    Tesamorelin's best-known trial reduced visceral fat in people with HIV-associated lipodystrophy.

    Mechanism map

    Evidence level: Clinical: phase 3 trial. All mechanism maps

    Tesamorelin mechanism diagramGHRH receptor agonism raising GH and IGF-1. Targets: GHRH receptor. Response: GH release ↑ → IGF-1 ↑. Effect reported: Visceral fat ↓.Tesamorelin mechanism mapGHRH receptor agonism raising GH and IGF-1Tesamorelinstabilised GHRH(1-44)GHRH receptoranterior pituitary [1]GH release ↑[1]IGF-1 ↑[1]Visceral fat ↓HIV-associated lipodystrophy [1]Evidence: Clinical: phase 3 trial. Numbers in brackets refer to the cited sources.usapeptidevendors.com · Research Use OnlyRECEPTORRESPONSEEFFECT REPORTED
    Trial results apply to the pharmaceutical product, not to research-catalog vials. Open SVG
    1. Falutz J et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357:2359-70.

  3. Compare two documented suppliers

    35 of 112 directory vendors list Tesamorelin; 16 name their testing lab.

  4. Verify the lot before use

    1. Purgo sells it as “Tesamorlin”. Make sure the COA names the analyte, not just the store label.
    2. Match the CAS number on the certificate to 218949-48-5.
    3. A 44-residue peptide should show a mass-spec identity near 5135.78 g/mol; HPLC purity alone doesn't confirm identity.
    4. 35 of the 112 vendors in our directory list Tesamorelin; 16 of those name the lab that tests it.

FAQ

What is Tesamorelin?

Full-length GHRH(1-44) analogue stabilised with a trans-3-hexenoyl group on the N-terminal tyrosine. Tesamorelin's best-known trial reduced visceral fat in people with HIV-associated lipodystrophy.

What are Tesamorelin's CAS number and molecular weight?

CAS 218949-48-5, formula C221H366N72O67S, 5135.78 g/mol, per KEGG DRUG D06655 and PubChem CID 16137828.

Where can US labs buy Tesamorelin?

Purgo Labs stocks it as “Tesamorlin”; code usapeptidevendors takes 25% off at checkout. This page also lists the best-documented second vendor from our 112-vendor directory.

Is research-grade Tesamorelin for human use?

No. Vendor material is sold for Research Use Only, not for human or veterinary use.